Summit Therapeutics Inc
SMMT18.940USD
+0.340+1.83%
Cierre 09/12, 16:00（ET）Cotizaciones retrasadas 15 min
14.07BCap. mercado
PérdidaP/E TTM
Más Datos de Summit Therapeutics Inc Compañía
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Información de la empresa
Símbolo de cotizaciónSMMT
Nombre de la empresaSummit Therapeutics Inc
Fecha de salida a bolsaOct 14, 2004
Director ejecutivoDr. Mahkam (Maky) Zanganeh
Número de empleados159
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 14
Dirección601 Brickell Key Drive
CiudadMIAMI
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal33131
Teléfono13052032034
Sitio Webhttps://www.smmttx.com/
Símbolo de cotizaciónSMMT
Fecha de salida a bolsaOct 14, 2004
Director ejecutivoDr. Mahkam (Maky) Zanganeh
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
556.09M
+0.06%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
556.09M
+0.06%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Latin America
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 23 de ago
Actualizado: sáb., 23 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Duggan (Robert William)
74.86%
Zanganeh (Mahkam)
4.81%
Baker Bros. Advisors LP
4.54%
Xia (Yu)
4.24%
Fidelity Management & Research Company LLC
1.24%
Otro
10.30%
Accionistas
Accionistas
Proporción
Duggan (Robert William)
74.86%
Zanganeh (Mahkam)
4.81%
Baker Bros. Advisors LP
4.54%
Xia (Yu)
4.24%
Fidelity Management & Research Company LLC
1.24%
Otro
10.30%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
84.35%
Investment Advisor
5.54%
Hedge Fund
5.14%
Investment Advisor/Hedge Fund
2.32%
Research Firm
0.25%
Sovereign Wealth Fund
0.19%
Pension Fund
0.07%
Bank and Trust
0.06%
Otro
2.09%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
447
727.40M
97.94%
-484.11K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Duggan (Robert William)
555.75M
74.83%
+74.55K
+0.01%
May 30, 2025
Zanganeh (Mahkam)
35.74M
4.81%
+359.73K
+1.02%
Apr 15, 2025
Baker Bros. Advisors LP
24.42M
3.29%
--
--
Mar 31, 2025
Xia (Yu)
31.52M
4.24%
--
--
Apr 15, 2025
Fidelity Management & Research Company LLC
9.31M
1.25%
+1.29M
+16.12%
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
1.57%
-30.07K
-0.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.51M
1.01%
-43.09K
-0.57%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
0.65%
-751.52K
-13.41%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.46M
0.87%
-11.97K
-0.19%
Mar 31, 2025
Soni (Manmeet Singh)
3.02M
0.41%
--
--
Apr 15, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Tema Oncology ETF
2.83%
ProShares Ultra Nasdaq Biotechnology
1.76%
Invesco Nasdaq Biotechnology ETF
1.76%
SPDR S&P Biotech ETF
1.07%
Invesco NASDAQ Next Gen 100 ETF
0.96%
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
Invesco ESG NASDAQ Next Gen 100 ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.61%
iShares Biotechnology ETF
0.25%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.21%
Ver más
Tema Oncology ETF
Proporción2.83%
ProShares Ultra Nasdaq Biotechnology
Proporción1.76%
Invesco Nasdaq Biotechnology ETF
Proporción1.76%
SPDR S&P Biotech ETF
Proporción1.07%
Invesco NASDAQ Next Gen 100 ETF
Proporción0.96%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.95%
Invesco ESG NASDAQ Next Gen 100 ETF
Proporción0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.61%
iShares Biotechnology ETF
Proporción0.25%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proporción0.21%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
